睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 36 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 36

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心江南大学附属医院Affiliated Hospital of Jiangnan University无锡医院页面
  3. 研究中心安徽省肿瘤医院Anhui Provincial Cancer Hospital合肥医院页面
  4. 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
  5. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  6. 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
  7. 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
  8. 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
  9. 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
  10. 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
  11. 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
  12. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  13. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  14. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  15. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  16. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  17. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  18. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  19. 研究中心LinYi Cancer Hospital临沂医院页面
  20. 研究中心南方医科大学南方医院Nanfang Hospital广州医院页面
  21. 研究中心南京鼓楼医院Nanjing Drum Tower Hospital南京医院页面
  22. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  23. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  24. 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
  25. 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
  26. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  27. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面
  28. 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
  29. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  30. 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
  31. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  32. 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面
  33. 研究中心空军军医大学唐都医院Tangdu Hospital西安医院页面
  34. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  35. 研究中心四川大学华西医院West China Hospital成都医院页面
  36. 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06345729,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)

    入选标准第 1 条

    Provides an archival tumor sample (≤5 years) or newly obtained core, incisional, or excisional biopsy or fine needle aspirate (FNA) of a tumor lesion, not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, programmed cell death ligand 1 (PD-L1) status, and biomarker research

    入选标准第 3 条

  3. Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8

    入选标准第 2 条

  4. If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load

    入选标准第 6 条

    Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention

    排除标准第 7 条

    Has received radiotherapy to non-central nervous system (CNS) disease within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis

    排除标准第 8 条

  5. Known additional malignancy that is progressing or has required active treatment within the past 3 years

    排除标准第 10 条

    Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

    排除标准第 13 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06345729,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
  2. Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8
  3. Provides an archival tumor sample (≤5 years) or newly obtained core, incisional, or excisional biopsy or fine needle aspirate (FNA) of a tumor lesion, not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, programmed cell death ligand 1 (PD-L1) status, and biomarker research
  4. If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to < Grade 1 or baseline
  5. If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)
  6. If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
  7. If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable

排除标准:Exclusion Criteria:

  1. Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elements are present, the participant is ineligible
  2. Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
  3. Has known history of, or active, neurologic paraneoplastic syndrome
  4. Has an active infection requiring systemic therapy, with exceptions
  5. Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  6. Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC
  7. Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
  8. Has received radiotherapy to non-central nervous system (CNS) disease within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis
  9. Has known active CNS metastases and/or carcinomatous meningitis
  10. Known additional malignancy that is progressing or has required active treatment within the past 3 years
  11. Has active autoimmune disease that has required systemic treatment in the past 2 years
  12. Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  13. Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  14. Has history of allogenic tissue/solid organ transplant
  15. Has not fully recovered from any effects of major surgical procedure

引自 ClinicalTrials.gov, NCT06345729, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06345729,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06345729